Amgen (AMGN) Announces Full Results from Part 1 of the Phase 2 study of MariTide

Amgen Inc. (NASDAQ:AMGN) is one of the 10 Best Value Stocks to Buy According to Billionaires. On June 23, the company announced full results from Part 1 of the Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133), which is a long-acting, peptide-antibody conjugate subcutaneously administered monthly or less frequently. In the Phase 2 study, MariTide exhibited up to ~20% average weight loss in people who are living with obesity without Type 2 diabetes (T2D) as compared with 2.6% in the placebo arm, and up to ~17% average weight loss in people who are living with obesity with T2D in comparison to 1.4% in the placebo arm, per the efficacy estimand.

Amgen Inc. (NASDAQ:AMGN) also added that weight loss had not plateaued by 52 weeks, which indicates the potential for further weight reduction. Apart from the meaningful weight loss, MariTide showcased a robust and sustained reduction in hemoglobin A1c (HbA1c) of up to 2.2% in people who have obesity and T2D. MariTide’s monthly or less frequent dosing can improve adherence and long-term weight control. This provides an opportunity to optimize health outcomes for people who have obesity, Type 2 diabetes, and related conditions, highlighted Amgen Inc. (NASDAQ:AMGN).

While we acknowledge the potential of AMGN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than AMGN and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.